Product
APG2575
3 clinical trials
4 indications
Indication
Chronic Lymphocytic LeukemiaIndication
Small Lymphocytic LymphomaIndication
Waldenstrom MacroglobulinemiaClinical trial
A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
APG-2575CU101, A Phase Ib Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLLStatus: Recruiting, Estimated PCD: 2025-03-30
Clinical trial
A Phase Ib /II Open-label, Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia (MAPLE-1)Status: Recruiting, Estimated PCD: 2024-12-30